IFN-γ Enhances the Antimyeloma Activity of the Fully Human Anti–Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3

Carlo‐Stella, Carmelo; Guidetti, Anna; Nicola, Massimo Di; Lavazza, Cristiana; Cleris, Loredana; Sia, Daniela; Longoni, Paolo; Milanesi, Marco; Magni, Michele; Nagy, Zoltán Á.; Corradini, Paolo; Carbone, Antonino; Formelli, Franca; Gianni, Alessandro M.

doi:10.1158/0008-5472.can-06-3744

Cited by 18 publications

(7 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A fully human anti-HLA-DR antibody, 1D09C3, has activity in both in vitro myeloma cell culture studies, as well as in vivo murine studies with myeloma xenografts. Pretreatment with interferon-c (IFNc) is noted to enhance its therapeutic effect (Nagy et al, 2002;Carlo-Stella et al, 2007). Humax-CD38 antibody is also a human anti-CD38 IgG1 antibody in preclinical development (Stevenson, 2006).…”

Section: Fully Human Antibodiesmentioning

confidence: 99%

Anti‐CD20 monoclonal antibody therapy in multiple myeloma

et al. 2008

View full text Add to dashboard Cite

SummaryCD20 is a particularly appealing target that is expressed on the surface of almost all B cells, with no significant shedding, secretion or internalization. In contrast to the demonstrated efficacy of anti-CD20 strategies in various B-cell lymphoproliferative disorders, the role of such therapy in multiple myeloma is undetermined and controversial. The expression of CD20 by myeloma cells is heterogeneous, and can be detected only in 13-22% of patients. However, there is increasing interest in testing anti-CD20 therapy in myeloma because of recent studies suggesting the existence of clonogenic CD20-positive precursor B cells in the disease. This article reviews the rationale, preclinical and clinical activity of anti-CD20 therapy in myeloma. Clinical trials show that anti-CD20 therapy with rituximab elicits a partial response in approximately 10% of CD20 + patients with multiple myeloma. In addition, there is preliminary evidence of disease stabilization in 50-57% of CD20 + patients for a period of 10-27 months. Further largescale clinical trials are therefore needed to establish the role of this promising strategy in the treatment of myeloma.

show abstract

Section: Fully Human Antibodiesmentioning

confidence: 99%

Anti‐CD20 monoclonal antibody therapy in multiple myeloma

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Additional MoAbs are directed against a variety of further MM cell targets including HLA‐DR by 1D09C3 and HLA class I by 2D7‐DB .…”

Section: Moabs Targeting Tumor Cellsmentioning

confidence: 99%

Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma

Allegra

Penna

Alonci

et al. 2013

European J of Haematology

View full text Add to dashboard Cite

Despite recent treatments, such as bortezomib, thalidomide, and lenalidomide, therapy of multiple myeloma (MM) is limited, and MM remains an incurable disease associated with high mortality. The outcome of patients treated with cytotoxic therapy has not been satisfactory. Therefore, new therapies are needed for relapsed MM. A new anticancer strategy is the use of monoclonal antibodies (MoAbs) that represent the best available combination of tumor cytotoxicity, environmental signal privation, and immune system redirection. Clinical results in patients with relapsed/refractory MM suggest that MoAbs are likely to operate synergistically with traditional therapies (dexamethasone), immune modulators (thalidomide, lenalidomide), and other novel therapies (bortezomib); in addition, MoAbs have shown the ability to overcome resistance to these therapies. It remains to be defined how MoAb therapy can most fruitfully be incorporated into the current therapeutic paradigms that have achieved significant survival earnings in patients with MM. This will require careful consideration of the optimal sequence of treatments and their clinical position as either short-term induction therapy, frontline therapy in patients ineligible for ASCT, or long-term maintenance treatment.

show abstract

“…[82] attested the efficacy of labeled 1D09C3 with technetium-99m to target HLA-DR antigens. Successful preclinical results in lymphoma [83] and myeloma, in combination with γ-IFN [84] have been reported. 1D09C3 received the orphan drug designation for the treatment of Hodgkin’s lymphoma by the European Medicines Agency (EMEA) in 2005.…”

Section: Antibodies Derived From Phage Display Libraries Used In Cmentioning

confidence: 99%

Antibody Phage Display Libraries: Contributions to Oncology

Dantas‐Barbosa

Brigido

Maranhão

2012

IJMS

View full text Add to dashboard Cite

Since the advent of phage display technology, dating back to 1985, antibody libraries displayed on filamentous phage surfaces have been used to identify specific binders for many different purposes, including the recognition of tumors. Phage display represents a high-throughput technique for screening billions of random fusion antibodies against virtually any target on the surface or inside cancer cells, or even soluble markers found in patient serum. Many phage display derived binders targeting important tumor markers have been identified. Selection directed to tumoral cells’ surfaces lead to the identification of unknown tumoral markers. Also the improvement of methods that require smaller amounts of cells has opened the possibility to use this approach on patient samples. Robust techniques combining an antibody library displayed on the phage surface and protein microarray allowed the identification of auto antibodies recognized by patient sera. Many Ab molecules directly or indirectly targeting angiogenesis have been identified, and one of them, ramucirumab, has been tested in 27 phase I–III clinical trials in a broad array of cancers. Examples of such antibodies will be discussed here with emphasis on those used as probes for molecular imaging and other clinical trials.

show abstract

IFN-γ Enhances the Antimyeloma Activity of the Fully Human Anti–Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3

Cited by 18 publications

References 59 publications

Anti‐CD20 monoclonal antibody therapy in multiple myeloma

Anti‐CD20 monoclonal antibody therapy in multiple myeloma

Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma

Antibody Phage Display Libraries: Contributions to Oncology

Contact Info

Product

Resources

About